Education
About Us
Working with TipRanks
Follow Us
Fresenius Medical Care Corp. (FMS)
NYSE:FMS
RESEARCH TOOLSreports
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.44Last Year’s EPS
0.36Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 1.03%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, successful cost-saving initiatives, and positive developments in Care Enablement. However, challenges such as elevated mortality rates and lower than expected volume growth in the U.S. dialysis business were noted. The strategic initiatives and innovation efforts like the FDA approval for the 5008X machine position the company for future growth.Company Guidance
During the Fresenius Medical Care's fourth quarter 2024 earnings call, CEO Helen Giza and CFO Martin Fischer highlighted the company's robust financial performance and strategic advancements. The company reported a Net Promoter Score of 72, reflecting strong patient satisfaction. Financially, Fresenius achieved 4% organic revenue growth and operating income margin improvements, with Care Delivery surpassing a 10% margin and Care Enablement reaching a 6.1% margin. The FME25 program exceeded its initial savings target, now aiming for €750 million by 2025. The value-based care business contributed €1.8 billion in revenue, with plans to reach €1.9 billion by 2025. Despite challenges like elevated mortality and lower-than-expected U.S. dialysis volume growth, the company maintained a positive outlook, projecting high teens to high 20s percent operating income growth for 2025. The strategic divestiture plan continued, with €750 million in cash proceeds realized by the end of 2024. The call also addressed the rollout of the 5008X Hemodiafiltration machine, anticipated to enhance U.S. market operations.Strong Financial Performance
Achieved 18% operating income growth at the upper end of earnings outlook for 2024, along with a 4% organic growth.
FME25 Transformation Program Success
Increased the total savings target from EUR650 million to EUR750 million by the end of 2025, exceeding the initial expectations.
Positive Developments in Care Enablement
Care Enablement improved its full-year margin to 6.1%, nearly tripling from the prior year, driven by volume growth and cost efficiencies.
Dividend Increase
Planning to propose a 21% increase in dividend, reflecting a strong financial policy and healthy cash flow.
FDA Approval and Innovation
Received FDA approval for the high-volume Hemodiafiltration-capable 5008X machine, with first treatments already conducted.
---
FMS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FMS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $23.31 | $23.45 | +0.60% |
| Nov 05, 2024 | $20.05 | $20.33 | +1.40% |
| Jul 30, 2024 | $20.36 | $19.63 | -3.59% |
| May 07, 2024 | $21.00 | $19.72 | -6.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fresenius Medical Care Corp. (FMS) report earnings?
Fresenius Medical Care Corp. (FMS) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Fresenius Medical Care Corp. (FMS) earnings time?
Fresenius Medical Care Corp. (FMS) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FMS EPS forecast?
FMS EPS forecast for the fiscal quarter 2025 (Q1) is 0.44.
---